Global markets are currently grappling with economic uncertainty and inflation fears, leading to declines in major U.S. stock indexes driven by trade policy concerns and consumer sentiment hitting a ...

Our fair value estimate of HKD 6.10 per share implies 2025 P/E of 13 times, 7 times EV/EBITDA and 5.5% dividend yield.

In the context of intensified competition in the domestic vaccine industry, AIM Vaccine's Hansen yeast recombinant hepatitis B vaccine saw an increase in sales revenue, standing firm against market ...